Pembrolizumab + Chemotherapy: a New Standard of Carefor Triple-Negative Breast Cancer

The 5-year follow-up data from the KEYNOTE 522 trial demonstrated the superior efficacy of the combination of pembrolizumab and chemotherapy, compared to chemotherapy alone, in treating triple negative breast cancer across various patients. Join us for an in-depth look at data from KEYNOTE 522, presented by Peter Schmid from the Barts Cancer Institute in London.